Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a TB vaccine shield healthcare workers from COVID-19?

NCT ID NCT04387409

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a vaccine called VPM1002 could help healthcare workers miss fewer days of work due to respiratory illnesses, including COVID-19. About 1,200 doctors, nurses, and other hospital staff received either the vaccine or a placebo. The goal was to see if the vaccine could boost the immune system and provide some protection against the coronavirus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

59 people

The number who actually took part.

Started

May 2020

Finished

Apr 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (≥18 years) * Male or female * Hospital personnel with expected high SARS-CoV-2 exposure * Subject is contractually capable, able to understand information on study and has signed informed consent sheet * Subject has access to an internet-enabled electronic device * Women of childbearing potential who are currently using reliable methods of birth control, have a negative pregnancy test during screening and have no intention to become pregnant for at least 3 months post-vaccination. Exclusion Criteria: * Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior BCG administration * Known active or latent Mycobacterium tuberculosis infection or with another mycobacterial species. A history with or suspicion of M. tuberculosis infection. * Fever (\>38 °C) within the past 24 hours * Pregnant or breast-feeding * Suspicion of active viral or bacterial infection * Participation of subject in another study within 30 days before screening and during this study * Person is an employee of the sponsor, a relative of the investigator or in direct reporting line to clinical trial staff at the clinical trial site * Severely immunocompromised subjects, such as: 1. subjects with known infection with the human immunodeficiency virus (HIV); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy and radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months * Active solid or non-solid malignancy or lymphoma in the past 5 years * Direct involvement in the design or the execution of the present clinical trial * Expected absence from work of ≥4 of the following 12 weeks due to any reason (holidays, maternity leave, retirement, planned surgery etc) * Employed to the hospital \< 22 hours per week * Previous positive SARS-CoV-2 test result

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infection, respiratory tract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ludwig-Maximilians-Universität München

    München, Bavaria, 80336, Germany

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, 30625, Germany

  • SocraTec R&D GmbH

    Erfurt, Thuringia, 99084, Germany